ATLANTA, GA — May 23, 2002 —
Tiotropium appears to improve lung volume, lung function, exercise endurance and dyspnea in patients with chronic obstructive pulmonary disease (COPD). Tiotropium is an inhaled anticholinergic used once per day.
Its bronchodilator effect occurs through prolonged M3-receptor antagonism. “These results confirm the link between improvements in lung volume and the ability to exercise for longer periods of time,” said one of the researchers, researcher Helgo Magnussen, MD, medical director of the Centre of Pneumology and Thoracic Surgery, Grosshansdorf, Germany.
“This translates into increased ability for COPD patients to participate in daily living.” The researchers presented the findings during two sessions at ATS 2002, the American Thoracic Society’s 98th International Conference. In a randomised, placebo-controlled study, 96 patients received tiotropium 18 µg once daily and 91 patients received placebo.
Baseline exercise tolerance was measured on a stationary bicycle at the start of the study, with the average endurance time for all patients measuring 8.2 minutes. After three weeks, patients receiving daily tiotropium could exercise for 1.1 minutes longer than those taking placebo. After six weeks, patients taking tiotropium could exercise for 1.75 minutes longer than patients taking placebo, a 20 percent improvement. The intensity of dyspnea was not different at the end of exercise at weeks 3 or 6 despite increased endurance time with tiotropium.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!